Evelo Biosciences (EVLO) Stock Statistics & Valuation Metrics

Evelo Biosciences has a market cap or net worth of $19.00. The enterprise value is $84.83.

Evelo Biosciences has 18,982,838 shares outstanding. The number of shares has decreased by -2.65% in one year.

Evelo Biosciences’s return on equity (ROE) is 22.94 and return on invested capital (ROIC) is -199.73%.

The current PE Ratio of Evelo Biosciences is ―. Evelo Biosciences’s PEG ratio is 0.03.

In the last 12 months, Evelo Biosciences had revenue of 0.00 and earned -114.53M in profits. Earnings per share was -26.28.

In the last 12 months, operating cash flow was -73.70M and capital expenditures -287.00K, giving a free cash flow of -73.99M billion.

Evelo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Evelo Biosciences upcoming earnings date is Aug 1, 2024, Before Open (Confirmed).

Evelo Biosciences as a current ratio of 4.16, with Debt / Equity ratio of -1024.40%

In the past 12 months, Evelo Biosciences has paid 930.00K in taxes.

Evelo Biosciences EV to EBITDA ratio is -1.35, with an EV/FCF ratio of -1.41.

Evelo Biosciences has $17.26M in cash and marketable securities with $33.95M in debt, giving a net cash position of -$16.69M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Evelo Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―